期刊
CLINICAL SCIENCE
卷 136, 期 1, 页码 29-44出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20210663
关键词
-
资金
- National Natural Science Foundation of China (NSFC) [82070768]
- Key Research and Development Program of Shaanxi Province [2021KW-53]
- Fundamental Research Funds for the Central Universities [xjj2018091]
- Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University [XJTU1AF-CRF-2019-008]
- Special Supportive Program for Organ Transplantation by COTDF [2019JYJH04]
This study investigated the regulatory function of WISP1 in kidney inflammation. The results showed that WISP1 can induce kidney inflammation and it can be prevented by inhibiting NF-KB. In addition, inhibition of WISP1 can suppress the production of inflammatory cytokines in macrophages and the proliferation of kidney fibroblasts. The increased expression of WISP1 in kidney inflammation models was also confirmed. Therefore, pharmacological blockade of WISP1 shows potential as a novel therapy for kidney inflammation.
Inflammation is a pathological feature of kidney injury and its progression correlates with the development of kidney fibrosis which can lead to kidney function impairment. This project investigated the regulatory function of WNT1-inducible signaling pathway protein 1 (WISP1) in kidney inflammation. Administration of recombinant WISP1 protein to healthy mice induced kidney inflammation (macrophage accrual and production of tumor necrosis factor alpha (TNF-alpha), CCL2 and IL-6), which could be prevented by inhibition of nuclear factor K-light-chain-enhancer of activated B cells (NF-KB). Furthermore, inhibition of WISP1, by gene knockdown or neutralising antibody, could inhibit cultured macrophages producing inflammatory cytokines following stimulation with lipopolysaccharides (LPSs) and kidney fibroblasts proliferating in response to TNF alpha, which both involved NF-KB signaling. Kidney expression of WISP1 was found to be increased in mouse models of progressive kidney inflammation-unilateral ureter obstruction (UUO) and streptozotocin (STZ)-induced diabetic nephropathy (DN). Treatment of UUO mice with WISP1 antibody reduced the kidney inflammation in these mice. Therefore, pharmacological blockade of WISP1 exhibits potential as a novel therapy for inhibiting inflammation in kidney disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据